dc.contributor.author |
London, GM
|
|
dc.contributor.author |
Khati, M
|
|
dc.contributor.author |
Mayosi, B
|
|
dc.date.accessioned |
2015-10-13T13:20:55Z |
|
dc.date.available |
2015-10-13T13:20:55Z |
|
dc.date.issued |
2014-10 |
|
dc.identifier.citation |
London, GM, Khati, M and Mayosi, B.2014. Potential of RNA aptamers in the prevention of HIV-1 subtype C infections. HIV Research for Prevention, Cape Town ICC, 27 -31 October 2014 |
en_US |
dc.identifier.uri |
http://hdl.handle.net/10204/8177
|
|
dc.description |
HIV Research for Prevention, Cape Town ICC, 27 -31 October 2014 |
en_US |
dc.description.abstract |
Compounds that have been used to prevent human immunodeficiency virus type-I (HIV-1) infections include synthetic chemicals, plant extras and monoclonal antibodies. Although most of these compounds have potent antiviral activity, they often fail to progress to later stages of clinical trials due to high toxicity and lack of specificity. Therefore, as an alternative to circumvent the above mentioned limitations we used aptamers, which are small nucleic acid ligands that recognize their target with high specificity and have no toxicity in clinical applications. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
PubMed |
en_US |
dc.relation.ispartofseries |
Workflow;14688 |
|
dc.subject |
RNA aptamers |
en_US |
dc.subject |
Human immunodeficiency virus |
en_US |
dc.subject |
Antivirals |
en_US |
dc.title |
Potential of RNA aptamers in the prevention of HIV-1 subtype C infections |
en_US |
dc.type |
Conference Presentation |
en_US |
dc.identifier.apacitation |
London, G., Khati, M., & Mayosi, B. (2014). Potential of RNA aptamers in the prevention of HIV-1 subtype C infections. PubMed. http://hdl.handle.net/10204/8177 |
en_ZA |
dc.identifier.chicagocitation |
London, GM, M Khati, and B Mayosi. "Potential of RNA aptamers in the prevention of HIV-1 subtype C infections." (2014): http://hdl.handle.net/10204/8177 |
en_ZA |
dc.identifier.vancouvercitation |
London G, Khati M, Mayosi B, Potential of RNA aptamers in the prevention of HIV-1 subtype C infections; PubMed; 2014. http://hdl.handle.net/10204/8177 . |
en_ZA |
dc.identifier.ris |
TY - Conference Presentation
AU - London, GM
AU - Khati, M
AU - Mayosi, B
AB - Compounds that have been used to prevent human immunodeficiency virus type-I (HIV-1) infections include synthetic chemicals, plant extras and monoclonal antibodies. Although most of these compounds have potent antiviral activity, they often fail to progress to later stages of clinical trials due to high toxicity and lack of specificity. Therefore, as an alternative to circumvent the above mentioned limitations we used aptamers, which are small nucleic acid ligands that recognize their target with high specificity and have no toxicity in clinical applications.
DA - 2014-10
DB - ResearchSpace
DP - CSIR
KW - RNA aptamers
KW - Human immunodeficiency virus
KW - Antivirals
LK - https://researchspace.csir.co.za
PY - 2014
T1 - Potential of RNA aptamers in the prevention of HIV-1 subtype C infections
TI - Potential of RNA aptamers in the prevention of HIV-1 subtype C infections
UR - http://hdl.handle.net/10204/8177
ER -
|
en_ZA |